23andMe, Oscar Health among CNBC's top 50 'disruptors' for 2018

CNBC released its sixth annual Disruptor 50 list May 22, counting healthcare and biotechnology companies among its ranking of private companies "changing the world."

CNBC's Disruptor 50 Advisory Council — a group of 52 innovation and entrepreneurship experts — determined and ranked almost 1,000 nominations on various quantitative metrics to select the final 50. In total, CNBC's 50 selections have raised almost $78 billion in venture capital.

Here are six of CNBC's healthcare-related picks.

7. 23andMe (valuation: $1.8 billion). A direct-to-consumer genetic testing company that boasts FDA approval of at-home genetic tests for 10 diseases and a growing foundation in medical research.

12. Oscar Health (valuation: $3.2 billion). A health insurance company focused on leveraging technology and incentives to improve user experience.

15. Progyny (valuation: $123.1 million). A benefits startup that offers plans to self-insured companies to help employees cover the cost of fertility treatments, such as in-vitro fertilization and egg freezing.

25. Zipline International (valuation: N/A). A drone service that delivers medicine and blood supplies to difficult-to-reach places in developing countries around the globe.

30. Veritas Genetics (valuation: N/A). A genomics company that offers consumers and physicians the ability to sequence and interpret an individual's entire genome for under $1,000.

46. Auris Health (valuation: $1.3 billion). A robotic medical company developing microtools to enable more accurate diagnosis of lung cancer.

To access CNBC's Disruptor 50 list, click here.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars